Ketoconazole therapy of progressive coccidioidomycosis. Comparison of 400- and 800-mg doses and observations at higher doses

John N. Galgiani, David A. Stevens, John R. Graybill, William E. Dismukes, Gretchen A. Cloud

Research output: Contribution to journalArticle

71 Scopus citations

Abstract

One hundred and twelve patients with progressive pulmonary, skeletal, or soft tissue infections caused by Coccidioides immitis were randomly assigned to treatment with 400 or 800 mg per day dosages of ketoconazole. During therapy, if response was unsatisfactory, the protocol provided for treatment with higher doses. With 400 mg, ketoconazole resulted in 23.2 percent successes, which was similar to 32.1 percent successes with 800-mg treatments (p = 0.29). An additional six of 23 patients in whom initial therapy failed and who later received 1,200 or 1,600 mg per day of ketoconazole also showed improvement. However, among patients completing successful courses of therapy, relapses were more frequent in those requiring higher than 400-mg dosages for their success. From these studies, it is concluded that ketoconazole in doses above those currently recommended offer little or no benefit for most patients with non-meningeal forms of coccidioidomycosis.

Original languageEnglish (US)
Pages (from-to)603-610
Number of pages8
JournalThe American journal of medicine
Volume84
Issue number3 PART 2
DOIs
StatePublished - Mar 1988

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Ketoconazole therapy of progressive coccidioidomycosis. Comparison of 400- and 800-mg doses and observations at higher doses'. Together they form a unique fingerprint.

  • Cite this